Vaxon Biotech – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Vaxon Biotech - Product Pipeline Review - 2012” provides data on the Vaxon Biotech’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vaxon Biotech’s corporate website, SEC filings, investor presentations and featured press releases, both from Vaxon Biotech and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Vaxon Biotech; Vaxon Biotech - Key Therapeutics; Vaxon Biotech - Pipeline Overview and Promising Molecules; Vaxon Biotech - News; Vaxon Biotech - Latest Updates; Vaxon Biotech - Pipeline; Vaxon Biotech - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Vaxon Biotech - Product Pipeline Review - 2012” provides data on the Vaxon Biotech’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vaxon Biotech’s corporate website, SEC filings, investor presentations and featured press releases, both from Vaxon Biotech and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Vaxon Biotech - Brief Vaxon Biotech overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vaxon Biotech human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vaxon Biotech with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vaxon Biotech’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Vaxon Biotech’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vaxon Biotech in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vaxon Biotech’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vaxon Biotech.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vaxon Biotech and identify potential opportunities in those areas.
Current R&D Portfolio of Vaxon Biotech; Vaxon Biotech - Key Therapeutics; Vaxon Biotech - Pipeline Overview and Promising Molecules; Vaxon Biotech - News; Vaxon Biotech - Latest Updates; Vaxon Biotech - Pipeline; Vaxon Biotech - Discontinued/Dormant Projects
Vaxon Biotech Snapshot
Vaxon Biotech Overview
Key Information
Key Facts
Vaxon Biotech – Research and Development Overview
Key Therapeutic Areas
Vaxon Biotech – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vaxon Biotech – Pipeline Products Glance
Vaxon Biotech Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Vaxon Biotech – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vaxon Biotech – Drug Profiles
Vbx-016
Product Description
Mechanism of Action
R&D Progress
Vbx-026
Product Description
Mechanism of Action
R&D Progress
Vx-001
Product Description
Mechanism of Action
R&D Progress
Vx-006
Product Description
Mechanism of Action
R&D Progress
Vaxon Biotech – Pipeline Analysis
Vaxon Biotech – Pipeline Products by Therapeutic Class
Vaxon Biotech – Pipeline Products by Route of Administration
Vaxon Biotech – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Vaxon Biotech, Deals Summary
Vaxon Biotech, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Vaxon Biotech, Key Information
Vaxon Biotech, Key Facts
Vaxon Biotech – Pipeline by Indication, 2012
Vaxon Biotech – Pipeline by Stage of Development, 2012
Vaxon Biotech – Monotherapy Products in Pipeline, 2012
Vaxon Biotech – Phase II, 2012
Vaxon Biotech – Pre-Clinical, 2012
Vaxon Biotech – Discovery, 2012
Vaxon Biotech – Pipeline By Therapeutic Class, 2012
Vaxon Biotech – Pipeline By Route of Administration, 2012
Vaxon Biotech, Deals Summary
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur
LIST OF FIGURES
Vaxon Biotech – Pipeline by Indication, 2012
Vaxon Biotech – Pipeline by Stage of Development, 2012
Vaxon Biotech – Monotherapy Products in Pipeline, 2012
Vaxon Biotech – Pipeline By Therapeutic Class, 2012
Vaxon Biotech – Pipeline By Route of Administration, 2012
Vaxon Biotech Overview
Key Information
Key Facts
Vaxon Biotech – Research and Development Overview
Key Therapeutic Areas
Vaxon Biotech – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Vaxon Biotech – Pipeline Products Glance
Vaxon Biotech Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Vaxon Biotech – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Vaxon Biotech – Drug Profiles
Vbx-016
Product Description
Mechanism of Action
R&D Progress
Vbx-026
Product Description
Mechanism of Action
R&D Progress
Vx-001
Product Description
Mechanism of Action
R&D Progress
Vx-006
Product Description
Mechanism of Action
R&D Progress
Vaxon Biotech – Pipeline Analysis
Vaxon Biotech – Pipeline Products by Therapeutic Class
Vaxon Biotech – Pipeline Products by Route of Administration
Vaxon Biotech – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Vaxon Biotech, Deals Summary
Vaxon Biotech, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Vaxon Biotech, Key Information
Vaxon Biotech, Key Facts
Vaxon Biotech – Pipeline by Indication, 2012
Vaxon Biotech – Pipeline by Stage of Development, 2012
Vaxon Biotech – Monotherapy Products in Pipeline, 2012
Vaxon Biotech – Phase II, 2012
Vaxon Biotech – Pre-Clinical, 2012
Vaxon Biotech – Discovery, 2012
Vaxon Biotech – Pipeline By Therapeutic Class, 2012
Vaxon Biotech – Pipeline By Route of Administration, 2012
Vaxon Biotech, Deals Summary
Vaxon Biotech Enters Into Co-Development Agreement With Institut Pasteur
LIST OF FIGURES
Vaxon Biotech – Pipeline by Indication, 2012
Vaxon Biotech – Pipeline by Stage of Development, 2012
Vaxon Biotech – Monotherapy Products in Pipeline, 2012
Vaxon Biotech – Pipeline By Therapeutic Class, 2012
Vaxon Biotech – Pipeline By Route of Administration, 2012